Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation

被引:125
作者
Shen, Hua [1 ]
Tesar, Bethany M. [1 ]
Walker, Wendy E. [1 ]
Goldstein, Daniel R. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
关键词
D O I
10.4049/jimmunol.181.3.1849
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TLR4 is a unique TLR because downstream signaling occurs via two separate pathways, as follows: MyD88 and Toll IL-1 receptor (TIR) domain-containing adaptor-inducing IFN-beta (TRIF). In this study, we compared and contrasted the interplay of these pathways between murine dendritic cells (DCs) and macrophages during LPS stimulation. During TLR4 activation, neither pathway on its own was critical for up-regulation of costimulatory molecules in DCs, whereas the up-regulation of costimulatory molecules was largely TRIF dependent in macrophages. LPS-induced secreted factors, of which type I IFNs were one of the active components, played a larger role in promoting the up-regulation of costimulatory molecules in macrophages than DCs. In both cell types, MyD88 and TRIF pathways together accounted for the inflammatory response to LPS activation. Furthermore, signaling of both adaptors allowed maximal T cell priming by LPS-matured DCs, with MyD88 playing a larger role than TRIF. In sum, in our experimental systems, TRIF signaling plays a more important role in LPS-induced macrophage activation than in DC activation.
引用
收藏
页码:1849 / 1858
页数:10
相关论文
共 30 条
[1]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]   Type I interferon dependence of plasmacytoid dendritic cell activation and migration [J].
Asselin-Paturel, C ;
Brizard, G ;
Chemin, K ;
Boonstra, A ;
O'Garra, A ;
Vicari, A ;
Trinchieri, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (07) :1157-1167
[3]   Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents [J].
Baldridge, JR ;
McGowan, P ;
Evans, JT ;
Cluff, C ;
Mossman, S ;
Johnson, D ;
Persing, D .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1129-1138
[4]   Modifying toll-like receptor 9 signalling for therapeutic use [J].
Bhattacharjee, RN ;
Akira, S .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2006, 6 (03) :287-291
[5]   Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help [J].
Garay, Ricardo P. ;
Viens, Patrice ;
Bauer, Jacques ;
Normier, Gerard ;
Bardou, Marc ;
Jeannin, Jean-Francois ;
Chiavaroli, Carlo .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 563 (1-3) :1-17
[6]   DC-based cancer vaccines [J].
Gilboa, Eli .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1195-1203
[7]   Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation [J].
Guiducci, Cristiana ;
Ott, Gary ;
Chan, Jean H. ;
Damon, Emily ;
Calacsan, Carlo ;
Matray, Tracy ;
Lee, Kyung-Dall ;
Man, Robert L. Coff ;
Barrat, Franck J. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (08) :1999-2008
[8]   Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways [J].
Hoebe, K ;
Janssen, EM ;
Kim, SO ;
Alexopoulou, L ;
Flavell, RA ;
Han, JH ;
Beutler, B .
NATURE IMMUNOLOGY, 2003, 4 (12) :1223-1229
[9]   Identification of Lps2 as a key transducer of MyD88-independent TIR signalling [J].
Hoebe, K ;
Du, X ;
Georgel, P ;
Janssen, E ;
Tabeta, K ;
Kim, SO ;
Goode, J ;
Lin, P ;
Mann, N ;
Mudd, S ;
Crozat, K ;
Sovath, S ;
Han, J ;
Beutler, B .
NATURE, 2003, 424 (6950) :743-748
[10]   Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation [J].
Hoshino, K ;
Kaisho, T ;
Iwabe, T ;
Takeuchi, O ;
Akira, S .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (10) :1225-1231